Shaanxi HuiKang Bio-Tech Co., Ltd., founded in 2001, is a biotechnology R&D platform company focusing on the biological regeneration engineering and applied science and technology research of "active proteins and peptides" in the frontier field of biotechnology. The proportion of scientific and technological personnel accounts for more than 37%. The business scope covers Class I New Drug, medical devices, biological high-tech skin care products, etc.
In 2010, the company established HuiKang Research Institute, successively invested nearly CNY100 million in scientific research, started and carried out research in the fields of genetic engineering and cell engineering, and comprehensively entered the biomedical industry. Huikang Biotechnology Industrial Park, which was put into use in 2019, as a new R & D and production base, covers an area of 42 Mu and a total construction area of 65,000 square meters.
At present, HuiKang Bio-Tech has a professional scientific research team with more than 70 experts, including industry elites and distinguished university professors. The team has maintained long-term exchanges and cooperation with oversea biological experts and scholars from Australia and Korea.HuiKang Bio-Tech R&D Center is the life science Teaching Practice Base of Northwest University, and jointly established R & D center with it; At the same time, The R&D center is also the Practice Base of Northwest University and Shaanxi University of Science and Technology. In 2017, the honors of Xi'an Post-doctoral Innovation Base, Xi'an Talent Work Innovation Experimental Base, and Xi'an Active Protein and Peptides Engineering Center were successively granted to R&D center.
截止2023年9月，慧康集团旗下子公司共有152项专利，其中国家发明专利75项、外观专利18项、实用新型专利29项，中国香港专利18项， 国际专利12项；现有国家I类新药1项，医疗器械2项，西安市博士后创新基地项目3项，重点科研项目13项。《镁合金-重组人源胶原复合膜的制备与测试》获教育部国家重点实验室项目资助，《先导多肽筛选中试共享服务平台》以及《重组人溶菌酶滴眼液》被评为陕西省科技厅重点研发项目，《六胜肽产业化项目》被评为西安市科技进步奖。六胜肽科研成果论文刊登在美国《I&EC Research》杂志的封面，重组人源胶原蛋白以及胶原海绵研究成果刊登在《International Journal of Biological Macromolecules》杂志。
By the end of September 2023, Huikang group had 152 patents, including 75 national invention patents, 18 appearance patents, 29 utility model patents, 18 Hong Kong patents and 12 international patents; At present, there are 1 national class I new drug, 2 medical devices, 3 Xi'an Post Doctoral innovation base projects and 13 key scientific research projects. The preparation and testing of magnesium alloy recombinant human collagen composite membrane was supported by the National Key Laboratory Project of the Ministry of education. The pilot peptide screening pilot test sharing service platform and recombinant human lysozyme eye drops were rated as key R & D projects of Shaanxi Provincial Science and technology department. The Liusheng peptide industrialization project was rated as Xi'an Science and technology progress award. The research results of Liusheng peptide were published on the cover of i&ec research, and the research results of recombinant human collagen and collagen sponge were published in the International Journal of biological macrocells.